Strontium-89 improves survival in advanced prostate cancer

By  

Inpharma, Vol. 1, Iss. 1274, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α_v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

By Chu Franklin   Picus Joel   Fracasso Paula   Dreicer Robert   Lang Zhihui   Foster Brenda  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 674-679

Springer Publishing Company

Access to resources Recommend Favorite

New therapies for castrate-resistant prostate cancer

By Williams Stephen B   Lay Aaron H   Lau Clayton S   Josephson David Y   Wilson Timothy G   Choueiri Toni K   Pal Sumanta K  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2069-2074

Informa Healthcare

Access to resources Recommend Favorite